- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- GLENMARK PHARMA
GLENMARK PHARMA Share Price 
(GLPH)
Here is the latest stock price and chart of Glenmark Pharma. For more details, see the Glenmark Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Apr 25, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)565.35 | Open (Rs) 579.60 | High (Rs) 581.55 | Low (Rs) 562.20 |
| % Change-2.48 | Volume 28,853 | Value (Rs) 16,489,050 | 52-Week H/L 930.00 / 517.40 |
| Live NSE Quotes | Apr 25, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)566.75 | Open (Rs) 584.95 | High (Rs) 584.95 | Low (Rs) 563.50 |
| % Change-2.30 | Volume 334,858 | Value (Rs) 191,959,910 | 52-Week H/L 908.90 / 517.05 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 43.75 | P/E Ratio (x) 12.92 | Market Cap (Rs m) 153,368.15 | P/BV (x) 3.41 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GLENMARK PHARMA Share Price Today:
GLENMARK PHARMA last traded price was down 2.5% to Rs 565.4 on the BSE. On the NSE, GLENMARK PHARMA last traded price was down 2.3% to Rs 566.8. The total volume of shares traded was 0.4 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.8%. And the benchmark S&P BSE SENSEX was at 34,501.3 (down 0.3%).
Over the last 30 days, the GLENMARK PHARMA share price is up 4.8%. And over the last one year, GLENMARK PHARMA share price is down 37.2%.
|
| |
Today's Market
Sensex Ends Day in Red; IT Stocks Rally(Closing)
After opening the day in red, share markets in India witnessed volatile trading activity throughout the day and ended the day in red.
Related Views On News
Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)
Nov 7, 2017Poor show in the US, Latam and India hit profits during the quarter.
Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)
Oct 30, 2017The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.
Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)
May 18, 2017Base price erosion in the US and lower Zetia sales impacts profits.
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
More Views on NewsMost Popular
Why India is Short of Cash Again(Vivek Kaul's Diary)
Apr 19, 2018It is basically a supply problem with not enough currency going around in the financial system.
A Sure Shot Way to Predict a Multibagger Stock(The 5 Minute Wrapup)
Apr 17, 2018The imaginary stock price of IIM Ahmedabad could have rivalled the returns from Titan and Asian Paints thanks to its enormous pricing power.
Why Buffett Would Scowl at My Latest Recommendation...(Profit Hunter)
Apr 18, 2018Warren Buffett's advice that may not be so relevant in these dynamic times, and could do investors more damage than good when taken at the face value.
This is How a Smart Robo-Advisor can Help You Chart Your Asset Allocation...(Outside View)
Apr 16, 2018PersonalFN explains how a dependable robo-advisory platform can help you create your personalized asset allocation plan
How Retail Investors Often Dump the Best Buying Opportunities(Chart Of The Day)
Apr 16, 2018A journey into how retail investors have invested since the turn of the millennium and why I don't want to do repeat that mistake ever again...
More|
| |
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 8-QTR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.